126 related articles for article (PubMed ID: 14583188)
1. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.
Erlandsson E; Andersson K; Cavallin A; Nilsson A; Larsson-Lorek U; Niss U; Sjöberg A; Wallén-Ohman M; Antonsson P; Walse B; Forsberg G
J Mol Biol; 2003 Nov; 333(5):893-905. PubMed ID: 14583188
[TBL] [Abstract][Full Text] [Related]
2. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
3. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
[TBL] [Abstract][Full Text] [Related]
4. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
[TBL] [Abstract][Full Text] [Related]
5. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
7. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld RA; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Immunol Immunother; 1995 Aug; 41(2):129-36. PubMed ID: 7656271
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of human colon cancer by antibody-targeted superantigens.
Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
[TBL] [Abstract][Full Text] [Related]
10. Genetically engineered superantigens as tolerable antitumor agents.
Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
[TBL] [Abstract][Full Text] [Related]
11. Selection of phage-displayed superantigen by binding to cell-surface MHC class II.
Wung JL; Gascoigne NR
J Immunol Methods; 1997 May; 204(1):33-41. PubMed ID: 9202707
[TBL] [Abstract][Full Text] [Related]
12. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
[TBL] [Abstract][Full Text] [Related]
13. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
14. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.
Lando PA; Dohlsten M; Ohlsson L; Kalland T
Int J Cancer; 1995 Aug; 62(4):466-71. PubMed ID: 7635573
[TBL] [Abstract][Full Text] [Related]
15. Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A.
Bavari S; Dyas B; Ulrich RG
J Infect Dis; 1996 Aug; 174(2):338-45. PubMed ID: 8699064
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
[TBL] [Abstract][Full Text] [Related]
17. T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.
Holzer U; Orlikowsky T; Zehrer C; Bethge W; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Immunology; 1997 Jan; 90(1):74-80. PubMed ID: 9038715
[TBL] [Abstract][Full Text] [Related]
18. A neutralizing epitope of the superantigen SEA has agonist activity on T cells.
Hobeika AC; Johnson HM
Biochem Biophys Res Commun; 1996 Jun; 223(3):565-71. PubMed ID: 8687436
[TBL] [Abstract][Full Text] [Related]
19. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies and superantigens: a novel therapeutic approach.
Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando PA; Björklund M
Med Oncol Tumor Pharmacother; 1993; 10(1-2):37-47. PubMed ID: 8258993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
